How Accurate Is a PET Scan for Lung Cancer?

The answer depends on what the scan is being asked to show. PET-CT is particularly useful for assessing the metabolic activity of a suspicious lung lesion and determining whether cancer may have spread to lymph nodes or other parts of the body. It is not, however, completely accurate, and it cannot replace a biopsy when tissue confirmation is needed.

That distinction matters. A PET scan is one part of the diagnostic and staging process, and its findings need to be interpreted alongside CT imaging, biopsy results and the wider clinical picture.

What Does a PET Scan Show in Lung Cancer?

In UK lung cancer care, PET is usually performed together with CT as a PET-CT scan. The two techniques provide different but complementary information.

Before the scan, a small amount of a radioactive tracer, usually fluorodeoxyglucose (FDG), is injected into the bloodstream. FDG behaves similarly to glucose. Many cancer cells use more glucose than surrounding healthy tissues, so areas of increased metabolic activity may show greater uptake on the PET images.

The CT component shows the anatomy: where a lesion is, how large it is, and its relationship to nearby structures. PET adds information about metabolic activity.

When arranging private lung cancer care, this information is especially valuable. It helps build a clear picture of whether the disease appears confined to the lung or has spread elsewhere, supporting a personalised treatment plan without unnecessary delay.

So, How Accurate Is PET-CT?

PET-CT is an important and well-established investigation in lung cancer, particularly for assessing whether cancer may have spread to lymph nodes or other parts of the body. However, there is no single accuracy percentage that applies to every patient or every use of the scan.

How reliable the result is depends on several factors, including the size and type of the tumour, its metabolic activity and the area of the body being assessed. Small or less metabolically active cancers can sometimes be missed, while infection and inflammation can produce increased FDG uptake that resembles cancer.

For this reason, PET-CT findings are interpreted alongside CT imaging, biopsy results and other clinical information. NICE recommends PET-CT before treatment for people with lung cancer who could potentially receive treatment with curative intent. Further lymph-node sampling may also be needed when findings would affect the treatment approach.

The Royal College of Radiologists recommends that  PET-CT happens within 6 weeks, and ideally within 4 weeks, of starting radical radiotherapy for lung cancer.

In practical terms, PET-CT can provide highly valuable information about the extent of lung cancer, but a positive or negative result does not always provide a definitive answer on its own.

Why Can a PET Scan Give a False Positive?

A PET-positive area is not automatically cancer.

FDG uptake reflects increased glucose metabolism, and cancer is not the only process that can cause this. Infection and inflammation can also produce increased uptake. Conditions such as tuberculosis and sarcoidosis are recognised causes of false-positive findings.

This means that a lymph node or lung lesion that shows increased activity on PET may require further investigation before it can be confirmed as malignant.

Where the result could significantly change treatment, obtaining tissue through a biopsy, endobronchial ultrasound (EBUS) or another appropriate procedure may be necessary.

Can a PET Scan Miss Lung Cancer?

Yes. A negative PET scan cannot completely exclude cancer.

Very small tumours can be difficult for PET-CT to detect because the scanner has limits to its spatial resolution. Certain types of tumour may also have relatively low FDG uptake and therefore appear less conspicuous on PET imaging.

British Thoracic Society guidance notes that false-negative results can occur with certain tumour types and that PET-CT has limitations when assessing some small or subsolid pulmonary nodules.

This is why a suspicious abnormality on CT should not automatically be dismissed because it shows little or no activity on PET.

Is PET-CT Used to Diagnose or Stage Lung Cancer?

PET-CT can contribute to the assessment of a suspicious lesion, but one of its most important roles in lung cancer is staging.

A scan can show that a lung lesion has features suspicious for cancer, but imaging alone does not establish exactly what type of cancer is present. Tissue sampling is generally required when pathological confirmation is needed.

This is why tests used to diagnose lung cancer often work together. CT identifies structural abnormalities, PET-CT provides metabolic and staging information, and biopsy establishes the pathology. Molecular testing may then provide further information that helps guide treatment. Dr Wilson's existing diagnostic guide uses the same overall sequence, describing PET-CT as a way of assessing spread while tissue sampling confirms the diagnosis.

How Does PET-CT Help Determine the Stage?

Cancer stage describes the extent of disease, and getting this right can fundamentally change the treatment plan.

PET-CT can identify metabolically active areas in lymph nodes or distant organs that may represent cancer spread. This can reveal areas of concern that were not apparent from the initial chest CT alone.

NICE recommends PET-CT before treatment for people with lung cancer who could potentially receive treatment with curative intent. When intrathoracic lymph nodes are enlarged, or PET-positive and their status would affect treatment, further sampling with techniques such as EBUS-TBNA or EUS-FNA may be required.

That second point is important. A PET-positive lymph node does not necessarily prove that cancer has spread there.

In the same way, a clear scan does not always mean that an established cancer stage changes, because staging is based on the full set of available findings rather than the appearance of one scan alone. Previous imaging, biopsy results and other evidence of disease can all remain relevant when the stage is assessed.

The difference between cancer stage and cancer grade can sometimes cause confusion. PET-CT contributes primarily to staging by helping establish where disease may be present; it does not determine how abnormal the cancer cells look under a microscope.

Does PET-CT Detect Metastatic Lung Cancer?

PET-CT can be particularly useful for identifying possible cancer deposits outside the lung, including in lymph nodes and certain distant organs.

If suspicious areas are identified, further imaging or biopsy may still be required. PET-CT also has limitations in some parts of the body. The brain, for example, normally has high glucose uptake, which limits the usefulness of FDG PET for detecting brain metastases. Dedicated brain imaging may therefore be required depending on the clinical situation.

For patients with metastatic lung cancer, accurate staging helps establish the extent of disease and informs decisions about systemic treatment, radiotherapy and other approaches.

What Happens If the PET Scan and Biopsy Do Not Agree?

Occasionally, different tests appear to tell different stories.

A lesion may look suspicious on CT but show little FDG uptake. A lymph node may be strongly PET-positive but contain no cancer when sampled. Alternatively, imaging may suggest relatively limited disease while another investigation identifies something that requires further assessment.

These situations do not necessarily mean that one test has failed. Each investigation provides different information.

The clinical team will consider the PET-CT findings alongside pathology, other scans, symptoms and the characteristics of the tumour. Sometimes another biopsy, repeat imaging or additional investigation is needed before the stage can be established confidently.

Discussing complex or conflicting results with a private oncology consultant can provide additional specialist input into how the imaging, pathology and other findings should be interpreted together.

If there is still uncertainty about staging or if a scan result would substantially change the proposed treatment, seeking a second opinion can provide another specialist review of the diagnosis and treatment options.

Can You Rely on a PET Scan for Lung Cancer?

PET-CT is one of the most useful imaging tools available for lung cancer staging, but it should not be viewed as a stand-alone test.

A positive result can sometimes reflect inflammation or infection. A negative result can occasionally miss small or less metabolically active cancers. The meaning of the scan therefore depends on the lesion being assessed and the other evidence available.

This is also why a pulmonary function test cannot detect lung cancer and why no single investigation should be expected to answer every diagnostic question. Different tests provide different pieces of information. Dr Wilson's existing article similarly distinguishes functional lung testing from CT, PET and biopsy used in lung cancer investigation.

The most reliable approach is to interpret PET-CT as part of the complete clinical picture rather than asking whether the scan is simply "positive" or "negative".

About Dr James Wilson

PET-CT provides important information about metabolic activity and the extent of lung cancer, but its results need to be interpreted alongside imaging, pathology and other investigations before major treatment decisions are made.

Dr James Wilson is a consultant clinical oncologist in full-time private practice in Central London, specialising in lung cancer and advanced radiotherapy. He helps patients understand complex scan and biopsy findings, establish what they mean for treatment planning and make informed decisions about their care.